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Structured Abstract 
 
Background and aims 
Since nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious upper gastrointestinal 
(GI) harm, guidelines have been established for the prescribing of proton pump inhibitors (PPIs) 
in high risk patients using NSAIDs. Studies looking into guideline compliance in surgical patients 
are scarce. Therefore, a retrospective cross-sectional database study was performed aimed at 
determining the proportion of non-compliance with the Dutch guideline, and at determining the 
association of several factors with this non-compliance. 
 
Materials and methods 
Included were hospital admissions of patients on surgical wards of Erasmus MC between 
January 1, 2013, to August 1, 2014 in which an NSAID was newly prescribed. Excluded was 
pre-admission PPI use. The main outcome was the proportion of non-compliance with the 
guideline. As a secondary outcome the association of several potential risk factors with non-
compliance was assessed. The proportion of guideline non-compliance was calculated as 
percentage of all included surgical ward admissions. For the secondary analysis, univariate and 
multivariable logistic regression analysis was performed. 
 
Results 
Fourhundred-and-nine admissions were included. The proportion of admissions in which 
guideline non-compliance was present was 46.6%, mostly due to incorrectly added PPIs. Coxib 
 
 
 
 
use (adjusted OR 0.22 (95% confidence interval 0.12-0.44), polypharmacy (the use of 5 or more 
drugs) (2.18 (1.27-3.76)) and the surgical wards orthopedics (22.32 (5.38-92.55)), plastic 
surgery (10.82 (2.51-46.59)), trauma surgery (5.78 (1.47-22.70)), and transplant/vascular 
surgery (4.45 (1.10-18.00)), were statistically significantly associated with non-compliance. 
 
Conclusion 
Non-compliance with the guideline on NSAID use and gastroprotection is present in almost half 
of surgical hospital admissions and mainly concerns overprescribing.  
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Introduction 
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are widely used for their analgesic, antipyretic, 
and anti-inflammatory effects[1,2].Upper gastrointestinal events with clinical symptoms occur in 
2.5-4.5% of patients and these are serious in approximately 1.0-1.5% of patients[3]. As the costs 
associated with these events are substantial, prevention by using gastroprotective strategies 
may be cost-effective, especially in high risk patients[4]. Therefore, guidelines have been 
implemented for the prescription of gastroprotective strategies in high risk patients. In the 
Netherlands the guideline ‘NSAID-use and prevention of gastric toxicity’ of the Dutch Institute for 
Health Care Improvement from 2003[5] and the HARM-wrestling recommendations from 2009[6] 
are the evidence based guidelines most broadly used. HARM stands for Hospital Admissions 
Related to Medication; the HARM-wrestling recommendations were based on the results of the 
HARM study[7].  
Both guidelines recommend a gastroprotective strategy in high risk patients (see table 1 for the 
recommendations in the guidelines).Comparable guidelines are published in other countries, but 
they are not always complied to. In the Netherlands, Sturkenboom et al. showed already in 2003 
that gastroprotective strategies were underused in patients on NSAIDs[8]. A very recent study 
showed that gastroprotection use had increased in time, but that there was still room for 
improvement[9]. These Dutch studies are confirmed by a large US study, also showing underuse 
of gastroprotection[10]. Another US study showed that reimbursement of medication plays an 
important role in underuse of gastroprotection[11]. 
Besides underutilization of gastroprotective agents, overuse is also common especially within 
hospitals[12,13]. Increasingly, studies on adverse drug reactions caused by PPIs are being 
published, contradicting the overall professional opinion regarding the high safety of this drug 
class. Hypomagnesemia[14], increased fracture risk[15], hypovitaminosis B12[16], and community 
 
 
 
 
acquired pneumonia[17] have all been linked to PPI use, although the evidence is rarely 
conclusive. Given these reports, it becomes increasingly important to only use PPIs when 
indicated. In hospitals NSAIDs are often initiated as postoperative analgesics and PPIs are co-
started as gastroprotective agents which may result in chronic PPI use: after the NSAID is 
stopped, the PPI is continued inadvertently[12]. This makes it all the more important to only add 
PPIs when strictly indicated. Therefore, we performed a study aimed to determine the non-
compliance with guidelines for prescribing PPIs as gastroprotective agents in NSAID users in 
surgical patients. Secondary aim was to determine risk factors associated with guideline non-
compliance. 
 
Methods 
 
Study design 
A single-center retrospective database study was conducted using data from the electronic 
patient record (Elpado, non-commercial homegrown system) of the Erasmus University Medical 
Center (Erasmus MC) in Rotterdam, the Netherlands. All data were handled confidentially. 
Patient and prescriber identification lists were made and the data were stored in a database in a 
coded way, not to be tracked back to the specific patient or prescriber. The study was 
conducted according to the Personal Data Protection Act. The Medical Research Ethics 
Committee (MREC) of Erasmus MC provided a waiver for the study. 
 
Study population 
The study base population comprised all hospital admissions of patients admitted to the surgical 
wards of Erasmus MC from January 1, 2013, to July 31, 2014 in which the patient received a 
 
 
 
 
nsNSAID (ATC code M01AB, M01AC, M01AE or coxib (ATC code M01AH) 
(http://www.whocc.no/atc_ddd_index/; accessed August 2015). From this base population a 
sample of hospital admissions was selected by including each 10th patient, with equal selection 
of all surgical wards. After reaching the end of the dataset, again every 10th patient of the 
remaining patients was selected, and so on. Each selected patient was first checked for the 
following inclusion and exclusion criteria. 
Inclusion criteria for admitted patients were 18 years and older of age and starting an NSAID 
while in hospital. Exclusion criteria were pre-hospital NSAID use continued during 
hospitalization, pre-hospital PPI use continued during hospitalization, or a combination of both, 
PPI prescription at least two hours prior to NSAID prescription in hospital, and dermal NSAID 
use. 
The selection was repeated until 250 eligible hospital admissions were included (see Data 
analysis for sample size collection). 
 
Data collection 
Eligible patients were selected from the computerized physician order entry system (Medicator®, 
CSC-Isoft, Leiden, The Netherlands), based on the use of nsNSAIDs or coxibs. General patient 
and medical data were collected from the electronic patient records: gender, date of birth, date 
of hospital admission, date of hospital discharge, the physician who prescribed the NSAID 
(coded by a number), name of surgical ward, name of NSAID, start date of NSAID prescription, 
stop date of NSAID prescription, daily NSAID dose, NSAID prescribed ‘as needed’ or not, 
number of medicines coprescribed with NSAID (NSAID included in counting), whether the 
patient had a history of a PUOB or not, whether the patient had a history of untreated H. pylori 
infection or not, relevant co-morbidities (rheumatoid arthritis, diabetes mellitus, cardiac failure) 
 
 
 
 
and how many if applicable, risk medication (according to guideline) present or not and how 
many and which class of risk medication if applicable, PPI use or not, start date and stop date of 
PPI use if applicable. 
We decided not to include comedication with non-oral anticoagulants or with spironolacton as 
risk medication, because neither were included in the alert system of Medicator, which is based 
on the national G-standard, a system of drug-drug interaction alerts. So, although spironolacton 
is mentioned in the guidelines as high-risk medication, the Dutch medication surveillance 
systems based on the G-standard do not alert for this medication.  
 
High-risk NSAID users and compliance with guideline on NSAID use and PPI prescription  
High-risk patients were defined according to the guideline of the Dutch Institute for Health Care 
Improvement and the HARM-wrestling report[6,7]. PPIs were assessed as needed when (a) the 
patient is 70 years of age or older, or has a history of gastric ulcer disease, or is infected with H. 
pylori or (b) the patient is between 60-70 years of age and has additional risk factors as 
described in the guidelines. Long term use of high dosages of NSAIDs was not applicable to our 
population, as the NSAIDs were mainly prescribed as postoperative analgesic. 
Non-compliance with the guideline was defined as PPI prescription when the patient was not at 
risk for gastrointestinal toxicity according to the guidelines, or PPI prescription when the patient 
was at risk for gastrointestinal toxicity but received a coxib (without aspirin as comedication), or 
no PPI prescription when the patient was at risk for gastrointestinal toxicity according to the 
guidelines. 
The appropriateness of coxib prescription (without a PPI) was not assessed in this study. 
 
 
 
 
 
Outcome 
The primary outcome was non-compliance with PPI prescribing as mentioned in the national 
evidence-based guidelines on NSAID use and gastroprotection. The secondary outcome was 
the association of several potential risk factors with non-compliance with the guideline. These 
potential risk factors were based on the risk factors from the guidelines (e.g. age) combined with 
some general risk factors for prescribing errors (e.g. polypharmacy): age at day of hospital 
admission (classified into subgroups according to the guidelines’ description of high-risk 
patients: below 60 years, 60-69 years and 70 years and older) and gender of the patient, 
surgical ward, type of NSAID (nsNSAID or coxib), polypharmacy defined as the use of five or 
more drugs concomitantly, duration of NSAID use, NSAID use as needed, history of an ulcer, 
number of relevant comorbidities, and the use of risk medication. 
 
Data monitoring 
A sample of 10% of the entered data in this form was checked for completeness and plausibility 
and for linkage to really existing patients by another person than the one entering it. Any 
systematic errors discovered in this sample were checked in the complete dataset and 
corrected where necessary. The complete dataset was also checked for outlier data and their 
validity was checked as well. 
 
Data analysis 
Data analysis was performed using IBM SPSS Statistics version 21.  
 
 
 
 
For the sample size, at least 10 cases of guideline non-compliance are required per studied 
potential risk factor. Thus we needed 100 cases for evaluating 10 potential risk factors. With an 
expected non-compliance rate of 40% 250 hospital admissions were needed.  
For the analysis of the primary outcome, the proportion of non-compliance with the guideline 
was calculated by dividing the number of hospital admissions with non-compliance by the total 
number of included admissions and expressed as the percentage of all included admissions. 
Also proportions for each type of non-compliance were calculated, namely PPI incorrectly added 
and PPI incorrectly not added. In addition, for the secondary analysis in this study, univariate 
and multivariable logistic regression analysis was performed. Potential risk factors with a 
statistically significant association in the univariate analysis, were entered into the multivariate 
model. When this changed the beta coefficient for at least 10%, the risk factor was retained in 
the model. Unadjusted and adjusted odds ratios (OR and ORadj) and their 95% confidence 
intervals (95% CIs) were calculated.  
 
Results 
The study base population consisted of 3181 hospital admissions. A random subset of 480 
hospital admissions was selected for screening of inclusion and exclusion criteria. In 231 
hospital admissions, at least one reason for exclusion was present. Thus 249 hospital 
admissions of 248 patients (one patient was admitted twice during the study period) met the 
inclusion criteria (figure 1). 
Table 2 shows the baseline patient characteristics of included hospital admissions. Mean age of 
the admitted patients was 43.5 (±17.7) years, with the majority of patients in the youngest age 
category (<60 years). During most hospital admissions the nsNSAID diclofenac or the COX-2 
selective NSAID etoricoxib were prescribed. In 48 (19.3%) admissions, the patient received the 
 
 
 
 
NSAID as needed. No patients had a history of untreated infection with H. pylori. The majority of 
patients did not have any comorbidities or risk medication. Diabetes mellitus was recorded in 10 
(4.0%) hospital admissions. In 19 (7.6%) hospital admissions the receiving patient had risk 
medication together with the prescribed NSAID. In one (0.4%) hospital admission the receiving 
patient had three of those medicines. There were no hospital admissions in which the patient 
had more than three of these medicines alongside the prescribed NSAID, nor hospital 
admissions in which the patient had more than one comorbidity.  
 
Guideline non-compliance 
In 116 hospital admissions non-compliance with the guideline on NSAID use and 
gastroprotection was identified, resulting in a proportion of 46.6%. In 108 (43.4% of all 
admissions; 93.1% of non-compliant admissions) admissions the PPI was incorrectly added and 
in 8 (3.2% of all admissions; 6.9% of non-compliant admissions) the PPI was incorrectly not 
added.  
 
Potential risk factors for non-compliance 
Unadjusted odds ratios of the univariate analysis of the association between several potential 
risk factors and non-compliance, are presented in table 3. Coxib use was inversely associated 
with guideline non-compliance. Polypharmacy and surgical ward type were found to be 
statistically significant associated with non-compliance. The same table shows the results of the 
multivariable analysis, for those factors that were statistically significantly associated with non-
compliance in the univariate analysis.  
 
 
 
 
Polypharmacy defined as the use of 5 or more drugs (OR 2.18 (1.27-3.76)) and the surgical 
wards orthopedics (OR 22.32 (5.38-92.55)), plastic surgery (OR 10.82 (2.51-46.59)), trauma 
surgery (OR 5.78 (1.47-22.70)), and transplant/vascular surgery (OR 4.45 (1.10-18.00)), were 
statistically significantly associated with non-compliance. Coxib use (adjusted OR 0.22 (95% 
confidence interval 0.12-0.44) was inversely associated with non-compliance in the multivariable 
analysis. 
 
Discussion 
This study shows that in almost half of the hospital admissions to surgical wards, PPI 
prescribing is not compliant with the national guidelines on NSAID use and gastroprotection. A 
significant inverse association of coxib use with guideline non-compliance was found in this 
study. This means that when a coxib is prescribed, physicians comply more with the guideline 
on NSAID use and gastroprotection. As coxibs form a gastroprotective strategy as such, PPIs 
are more often correctly not coprescribed. This study also showed that polypharmacy and 
specific surgical wards are associated with guideline non-compliance. With an increasing 
number of medicines, it may become more difficult for doctors to interpret the guideline 
correctly. Specific ward protocols and/or culture may explain the differences between wards. 
Especially, orthopedic and plastic surgery wards seem to perform less than other wards. Our 
study was not designed to clarify the reasons for this and studies in other hospitals are needed 
to confirm this finding. Nevertheless, the variation of guideline non-compliance between surgical 
ward types may be the focus for tailored interventions to improve compliance.  
We are not aware of any other study reporting on compliance with guidelines on NSAID use and 
gastroprotection among patients admitted to surgical wards. However, compliance with 
guidelines for PPI prescriptions has been investigated in other settings[8-11,18]. These studies 
 
 
 
 
have shown that compliance is low and PPIs are generally underprescribed. In contrast, this 
study showed that PPIs are generally being overprescribed. Several studies have confirmed 
overprescribing of PPIs, as we have found in our study[12,13]. One of these studies has been 
performed (partly) in the same hospital as ours, but in another type of ward, namely pulmonary 
medicine ward[13]. On such a ward NSAIDs are not used for purely postoperative reasons, as is 
mainly the case on the surgical wards in our study. We hypothesize that the main reason for 
overprescription in our study is a gap in the knowledge of the national guidelines and local 
protocols in the surgically oriented doctors and nurses. This can result in an unfounded fear for 
gastric complications. As a consequence of the very high incidence of NSAID prescription in 
surgical wards, the accompanying gastroprotection may come too easily along with it (“it doesn’t 
harm to try”). As most studies on gastrointestinal toxicity and risk factors involve patients on 
chronic NSAID therapy, the guidelines on gastroprotection are also based on such long term 
NSAID use. Little is known on the effect of gastroprotection in short term use of NSAIDs, 
making careful selection of PPI prescription even more important, especially since PPI’s are 
often inadvertently continued even though the NSAID has been stopped.  
The strengths of this study are the complete medication data that are available in the 
computerized physician order entry system, allowing accurate retrospective assessment of drug 
exposure. The use of the hospital database allowed the identification of all patients prescribed 
NSAIDs during the study period and assessment of individual patient and treatment 
characteristics that are important in determination of compliance.  
Some potential limitations were present in this study. First, because of the retrospective design 
of this study, we could have missed essential data for the determination of compliance with the 
guidelines. Second, indications for the prescribed PPI were most of the time not recorded. It 
could be the case that the patient had other symptoms and the PPI was prescribed for another 
indication than as co-medication with an NSAID. Therefore, we may have overestimated the 
 
 
 
 
number of patients with non-compliance. However, we prevented this as much as possible, by 
excluding patients who received the PPI at least two hours before the NSAID. In addition, most 
PPI’s were prescribed at exactly the same time as the NSAID, rendering an alternative 
indication more unlikely. Third, it was not always obvious whether the patient had the NSAID or 
PPI or both prescribed in hospital, or whether the patient had the medication already from 
home, adopted in hospital by the prescribing physician. This could have led to inclusion of 
patients who should actually have been excluded, and thus this could have led to an 
overestimated effect. However, determination of whether the medication was from home or not 
was carried out in a standardized manner. Also, as many resources as possible were used to 
determine whether the medication was from home, so we do not expect a major bias due to this. 
Finally, this study was carried out in a single center setting which may limit the generalizability of 
our results. However, we know that in many surgical wards not prescibing gastroprotection 
along a NSAD is more or less considered an omission. We thus plead for better teaching of 
surgical doctors and nurses. 
In the current study, we did not investigate non-compliance with guidelines in a multicenter 
setting with larger numbers of patients; this is subject for future research. Another interesting 
topic for future research is the investigation of coxib prescribing compliance with guidelines. 
Finally, additional research is necessary on interventions aimed at improving guideline 
compliance.  
In conclusion, non-compliance with the national evidence-based guideline on NSAID use and 
PPI prescription as gastroprotection is high, mostly because PPIs are being overprescribed. 
Improvement is necessary and could be focused on the risk factors identified in this study. Such 
improvements may lead to substantial cost-savings and the prevention of PPI related toxicity.  
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Figure 1: Study flow 
 
 
 
